Our Science

Be Bio is a leader in developing engineered B cells as a new category of cellular medicines. B cells are one of the most unique and versatile populations of cells in the body, playing a key role in humoral immunity and in modulating immune cell behavior in tumors and chronically inflamed tissues. They are among the human body’s most prolific secreted protein factories, they traffic to tissues in a targetable fashion, and they can engraft in niches for as long as decades.
 

Our goal is to harness B cells’ rich biology and intrinsic drug-like properties by precisely engineering them to forge a new category of cell therapy. B cells address some of the major hurdles of cell & gene therapies today, such as inability to redose, unpredictable PK/PD, and the need to treat patients with toxic chemotherapy regimens prior to administering the cell therapy. B cell medicines are designed to be durable, re-dosable and can be administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, infectious disease, and enzyme deficiencies. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD and Richard James, PhD, Be Bio is re-imagining medicine based on the power of B cell therapy.

Our Team

Management and Board

David Steinberg, MBA
Co-founder and CEO

Aleks Radovic-Moreno, PhD
Co-founder and President

Lea Hachigian, PhD
Co-founder

Jason Rhodes, MBA
Director

Josh Resnick, MD, MBA
Director

Dan Janney, MBA
Director

Scientific Advisory Board

David Rawlings, MD

Shiv Pillai, MD, PhD

Richard James, PhD

Jason Cyster, PhD

Join Us

Be Bio is looking for motivated scientists to join its growing team.
Please contact careers@be.bio for more information.

Contact Us

One Kendall Sq. 
B200, Suite 001

Cambridge, MA 02139